Author details

Full Name

William F Symmans

Affiliation

ORCID

Career Start Year

1991

Papers

314

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37500962	Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes.	Breast Cancer Res Treat	2023
36270909	Molecular testing opportunities on cytology effusion specimens: the pre-analytic effects of various body fluid cytology preparation methods on RNA extraction quality and targeted sequencing.	Journal of the American Society of Cytopathology	2023
37608772	Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer	J Pathol	2023
37608771	Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.	J Pathol	2023
37923752	Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.	Nat Commun	2023
38086377	Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.	Cell Rep Med	2023
37712171	Pre-analytical effects on whole transcriptome and targeted RNA sequencing analysis in cytology: The effects of prolonged time in storage of effusion specimens prior to preservation.		2023
37547448	PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens.	Ther Adv Med Oncol	2023
36585450	Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.	Nat Cancer	2023
36650408	Assessment of stained direct cytology smears of breast cancer for whole transcriptome and targeted messenger RNA sequencing.		2023
36649570	Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial.	J Clin Oncol	2023
37146605	Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.	Cancer Cell	2023
37017812	HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.		2023
37325931	Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial.	Ann Surg	2023
37262407	Reply to Y. Wang et al and Q. Sui et al.		2023
37450351	Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer.	Cancer Res	2023
37318349	Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.		2023
36627285	Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer.		2023
37444385	Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial.	Cancers (Basel)	2023
37061619	A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.		2023
36689560	Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma.	Clin Cancer Res	2023
37231022	Simple combination of multiple somatic variant callers to increase accuracy.		2023
37043123	Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy.	Invest New Drugs	2023
36989609	Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer.	J Clin Oncol	2023
35093516	Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.	Annals of Oncology	2022
35903747	Network Modeling of Complex Time-Dependent Changes in Patient Adherence to Adjuvant Endocrine Treatment in ER+ Breast Cancer.	Frontiers in Psychology	2022
35653124	Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031).	Clin Cancer Res	2022
35513244	Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.	Ann Oncol	2022
35623341	Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.	Cancer Cell	2022
36069821	Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.	JAMA Surg	2022
35404674	Challenges and Gaps in Clinical Trial Genomic Data Management.	JCO Clin Cancer Inform	2022
35976643	Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy.	Arch Pathol Lab Med	2022
36456573	Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.	NPJ Breast Cancer	2022
35240097	Survivorship after neoadjuvant chemotherapy - Authors' reply.	Lancet Oncol	2022
35267631	Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer.	Cancers (Basel)	2022
34902335	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.	Lancet Oncol	2022
34782721	Correction to: Hormonal modulation of ESR1 mutant metastasis.	Oncogene	2022
35201273	Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer-Reply.	JAMA Oncology	2022
34529000	Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.	JAMA Oncol	2021
33541297	Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples.	BMC Cancer	2021
33617937	Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.	Ann Oncol	2021
33507815	Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.	J Clin Oncol	2021
34143979	Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.	Cancer Cell	2021
34092112	Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.	J Clin Oncol	2021
34253579	Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.	Clin Cancer Res	2021
33599688	Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.	JAMA Oncol	2021
32984932	A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer.	Invest New Drugs	2021
34741023	Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trial.	Nat Commun	2021
34389608	Interpreting the Complex Landscape of Immune-Tumor Interface.	Clinical Cancer Research	2021
34611148	Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.	NPJ Breast Cancer	2021